InvestSMART

Australian Pharmaceutical Industries Limited (ASX: API) - Announcements

DELISTED - Current share price for API : $1.530

ASX company news and announcements for Australian Pharmaceutical Industries Limited (API) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Pharmaceutical Industries Limited (API) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Pharmaceutical Industries Limited (API), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Pharmaceutical Industries Limited (API)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Notice of ceasing to be a substantial holder from BKW 18 Oct 2021 10:31AM $1.510 $1.530 risen by 1.32%
- Ceasing to be a substantial holder from SOL 18 Oct 2021 9:06AM $1.520 $1.530 risen by 0.66%
- Change in substantial holding 15 Oct 2021 4:10PM $1.518 $1.530 risen by 0.82%
- Legal Action Against API 11 Oct 2021 9:40AM $1.505 $1.530 risen by 1.66%
- API Raises Profit Guidance & Advises Full Year Results Date 11 Oct 2021 9:30AM $1.505 $1.530 risen by 1.66%
- WES: Acquisition of 19.3 per cent stake in API 7 Oct 2021 9:06AM $1.500 $1.530 risen by 2%
- SIG: Proposal to merge with API 27 Sep 2021 9:24AM $1.465 $1.530 risen by 4.44%
- Unsolicited, Non-binding, Conditional Proposal from Sigma 27 Sep 2021 9:05AM $1.465 $1.530 risen by 4.44%
- WES: Proposal to acquire API - update 16 Sep 2021 9:51AM $1.270 $1.530 risen by 20.47%
- Revised Non-Binding Indicative Proposal from Wesfarmers 16 Sep 2021 9:45AM $1.270 $1.530 risen by 20.47%
- MDR: MedAdvisor signs 5 year agreement with API 30 Jul 2021 8:50AM $1.440 $1.530 risen by 6.25%
- API Board rejects indicative proposal from Wesfarmers 29 Jul 2021 8:34AM $1.410 $1.530 risen by 8.51%
- Notice of initial substantial holder from WES 12 Jul 2021 8:53AM $1.145 $1.530 risen by 33.62%
- WES:Proposal to acquire Australian Pharmaceutical Industries 12 Jul 2021 8:51AM $1.145 $1.530 risen by 33.62%
- Conditional proposal for API from Wesfarmers 12 Jul 2021 8:42AM $1.145 $1.530 risen by 33.62%
- API strategic review and trading update 12 Jul 2021 8:33AM $1.145 $1.530 risen by 33.62%
- Initial Director's Interest Notice 7 Jun 2021 5:37PM $1.145 $1.530 risen by 33.62%
- Director Appointment 7 Jun 2021 9:45AM $1.160 $1.530 risen by 31.90%
- API Letter to Shareholders - Interim Dividend Payment 4 Jun 2021 9:41AM $1.150 $1.530 risen by 33.04%
- Pfizer distribution of medicines through API 19 May 2021 5:59PM $1.110 $1.530 risen by 37.84%
- API HY21 Results Presentation 22 Apr 2021 9:09AM $1.360 $1.530 risen by 12.50%
- API HY21 Results ASX Release 22 Apr 2021 9:05AM $1.360 $1.530 risen by 12.50%
- Dividend/Distribution - API 22 Apr 2021 9:01AM $1.360 $1.530 risen by 12.50%
- Half Year Accounts 22 Apr 2021 8:55AM $1.360 $1.530 risen by 12.50%
- API - HY21 Results Webcast Invitation 16 Apr 2021 3:48PM $1.350 $1.530 risen by 13.33%

76 - 100 of 477 results

Page 4 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.